Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care?

Future Oncology May 2017, Vol. 13, No. 11, Pages 951-953.


from Cancer via ola Kala on Inoreader http://ift.tt/2pWeOUL
via IFTTT